VivoSim LabsFRA:4OR 39 PEG Ratio is 0.05 as of Jun. 25, 2026, which is 44% below its 10-year median of 0.09. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.13. The stock has 4 warning signs investors should review. Among 95 Biotechnology companies, VivoSim Labs ranks better than 98.95% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for VivoSim Labs's PEG Ratio or its related term are showing as below:
FRA:4OR'
s PEG Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.09 Max: 0.14
Current: 0.02
During the past 13 years, VivoSim Labs's highest PEG Ratio was 0.14. The lowest was 0.02. And the median was 0.09.
FRA:4OR's PEG Ratio is ranked better than 98.95% of 95
companies
in the Biotechnology industry
Industry Median: 1.91
vs FRA:4OR: 0.02
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
VivoSim Labs (FRA:4OR) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
VivoSim Labs PEG Ratio Related Terms
VivoSim Labs PEG Ratio Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VivoSim Labs's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's PEG Ratio distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
VivoSim Labs (FRA:4OR) has a PEG Ratio of 0.05 as of Jun. 25, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on VivoSim Labs and its competitors. This is 44% below median its historical median of 0.09. Over the past decade, VivoSim Labs' PEG Ratio has ranged from 0.02 to 0.14. According to the industry distribution chart, VivoSim Labs ranks #1 out of 95 companies in the Biotechnology industry, placing it in the top 1.1%.
Is VivoSim Labs' PEG Ratio too high?
VivoSim Labs' current PEG Ratio of 0.05 is 44% below median its 10-year median of 0.09. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.14. The Biotechnology industry median PEG Ratio is 1.91. VivoSim Labs' value of 0.05 is 97.4% below this industry median. Based on the distribution chart, VivoSim Labs ranks #1 out of 95 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' PEG Ratio compare to AZTR and GRI?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #1 out of 95 companies for PEG Ratio. This places VivoSim Labs in the top 1% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.91. VivoSim Labs' value of 0.05 is 97.4% below this benchmark. Historically, VivoSim Labs' own PEG Ratio has ranged from 0.02 to 0.14 over the past decade. While the company's 10-year median is 0.09 vs. the industry median of 1.91, VivoSim Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.91, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current PEG Ratio of 0.05 is 97.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current PEG Ratio is 0.05, which is 44% below median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current PEG Ratio of 0.05. The stock's GF Value™ is €8.13, compared to a current price of €3.49 — trading 57% below its estimated fair value. The current PEG Ratio is 0.05, which is 44% below median its 10-year median of 0.09 and 97.4% below the Biotechnology industry median of 1.91. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current PEG Ratio is 0.05 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 57% below its estimated GF Value™ of €8.13.
Key valuation signals for FRA:4OR:
PEG Ratio: 0.05 (44% below median its 10-year median of 0.09)
GF Value™: €8.13 vs. price of €3.49 (57% below fair value)
Industry Position: 97.4% below the Biotechnology median (#1 of 95)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score
Get the complete analysis for FRA:4OR
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
